190
Participants
Start Date
December 10, 2024
Primary Completion Date
March 11, 2028
Study Completion Date
March 11, 2029
PF-07985045
KRAS inhibitor
Gemcitabine
Chemotherapy (antimetabolite)
Nab-paclitaxel
Taxane-type Chemotherapy
Cetuximab
Monoclonal Antibody (EGFR Inhibitor)
Fluorouracil
"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
Oxaliplatin
"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
Leucovorin
"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
Bevacizumab
VEG-F inhibitor
Pembrolizumab
immune checkpoint inhibitor (PD-1 inhibitor
Sasanlimab
immune checkpoint inhibitor (PD-1 inhibitor)
pemetrexed
"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
Cisplatin
"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
Paclitaxel
"Can be used in Platinum-based chemotherapy regimen~Taxane"
Carboplatin
"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
PF-07284892
SHP2 Inhibitor
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
University of Wisconsin Carbone Cancer Center-University Hospital, Madison
NOT_YET_RECRUITING
Highlands Oncology Group, Fayetteville
NOT_YET_RECRUITING
Highlands Oncology Group, Rogers
NOT_YET_RECRUITING
Highlands Oncology Group, Springdale
NOT_YET_RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
DFCI Chestnut Hill, Newton
NOT_YET_RECRUITING
National Cancer Center Hospital East, Kashiwa
NOT_YET_RECRUITING
Shizuoka Cancer Center, Nagaizumi-cho
RECRUITING
Pan American Center for Oncology Trials, LLC, Rio Piedras
Lead Sponsor
Pfizer
INDUSTRY